IDL Diagnostics AB (publ) (STO:IDLDX)

Market Cap	103.20M
Revenue (ttm)	54.81M
Net Income (ttm)	-46.07M
Shares Out	230.36M
EPS (ttm)	-0.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	210
Average Volume	282,439
Open	0.4590
Previous Close	0.4100
Day's Range	0.4480 - 0.4590
52-Week Range	0.3460 - 0.6500
Beta	0.87
RSI	44.90
Earnings Date	Aug 21, 2025

About IDL Diagnostics AB

IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) in May 2025. IDL Diagnostics AB (publ) was incorporated in 2000 and is based in Stockholm, S...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2000
• Employees: 20
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: IDLDX

Financial Performance

In 2024, IDL Diagnostics AB's revenue was 57.44 million, an increase of 33.45% compared to the previous year's 43.04 million. Losses were -42.45 million, -28.41% less than in 2023.